KUALA LUMPUR, May 27 -- Crown Bioscience has announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO).
According to a statement, this marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug discovery services.
The newly available models join CrownBio’s established and ever-expanding platform of PDX-derived organoids (PDXO).
PDXO are generated using HUB protocols to derive tumour organoids from CrownBio’s PDX collection, which is the world’s largest commercially available panel of PDX.
The complementary panels of patient and PDX-derived organoids, alongside parental PDX models, provide the opportunity to change the way drug discovery is conducted.
The combined collection of in vitro and in vivo patient-derived models are clinically relevant and predictive, and the matched model pairs offer a more efficient and informed transition from in vitro to in vivo studies to help reduce the currently high attrition rates of anticancer agents.
Benefits of the newly available PDO models include the availability of non-malignant, healthy tissue-derived organoids. This enables PDO studies to be well controlled for studying compound toxicity and therapeutic windows, including matched tissue controls.
CrownBio’s organoid platform is available to clients globally. The newly acquired PDO models have completed transfer to CrownBio. They are available for client studies immediately for efficacy and potency evaluation, combination strategy optimisation and lead candidate selection.
-- BERNAMA
No comments:
Post a Comment